$202.8 M

AGLE Mkt cap, 16-Aug-2018
Aeglea Biotherapeutics Net income (Q2, 2018)-17.5 M
Aeglea Biotherapeutics EBIT (Q2, 2018)-17.9 M
Aeglea Biotherapeutics Cash, 30-Jun-201820.6 M

Aeglea Biotherapeutics Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

18.1 m22.8 m

General and administrative expense

8.4 m10.1 m

Operating expense total

26.5 m32.9 m

EBIT

(21.9 m)(27.7 m)

Interest income

244 k482 k

Net Income

(21.7 m)(27.2 m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

3.6 m4.4 m5.4 m4.9 m5.8 m6.9 m16 m

General and administrative expense

1.8 m2.4 m2.1 m2.4 m2.4 m2.9 m5.8 m

Operating expense total

5.4 m6.9 m7.5 m7.3 m8.2 m9.8 m21.8 m

EBIT

(4.6 m)(5.5 m)(6.3 m)(6.3 m)(6.7 m)(8.2 m)(17.9 m)

Interest income

26 k74 k72 k95 k100 k143 k406 k

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)(6.6 m)(8.1 m)(17.5 m)

Aeglea Biotherapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

47.7 m12.8 m

Accounts Receivable

164.2 m

Inventories

1.7 m

Current Assets

66.4 m55 m

PP&E

599 k854 k

Total Assets

67.1 m56.1 m

Accounts Payable

168 k389 k

Current Liabilities

4 m5.6 m

Total Liabilities

4.1 m5.7 m

Additional Paid-in Capital

108.2 m123 m

Retained Earnings

(45.3 m)(72.5 m)

Total Equity

63 m50.3 m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

24 m70.6 m49.5 m16.8 m26.9 m10.8 m20.6 m

Current Assets

35.2 m76.9 m71.7 m60.3 m66.2 m48.8 m78.9 m

PP&E

321 k377 k342 k822 k802 k810 k776 k

Total Assets

35.5 m77.3 m72.1 m61.3 m67.1 m49.8 m79.7 m

Accounts Payable

509 k348 k523 k267 k634 k763 k952 k

Current Liabilities

3.8 m3.4 m3.8 m4 m4.4 m5.8 m6.2 m

Total Liabilities

3.8 m3.4 m3.9 m4.1 m4.5 m5.9 m6.3 m

Additional Paid-in Capital

1.5 m107.5 m108 m108.7 m120.8 m124.6 m163.5 m

Retained Earnings

(28.1 m)(33.6 m)(39.8 m)(51.5 m)(58.2 m)(80.6 m)(90 m)

Total Equity

73.9 m68.2 m57.2 m62.6 m43.9 m73.4 m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x1.1 x

Aeglea Biotherapeutics Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(21.7 m)(27.2 m)

Depreciation and Amortization

132 k249 k

Accounts Receivable

(43.6 k)

Inventories

(96.1 k)

Accounts Payable

(8 k)164 k

Cash From Operating Activities

(18.8 m)(24.6 m)

Purchases of PP&E

(212 k)(619 k)

Cash From Investing Activities

(12.1 m)(22.5 m)

Cash From Financing Activities

49.4 m12.2 m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)(8.1 m)(17.5 m)

Depreciation and Amortization

70 k145 k

Accounts Payable

509 k348 k523 k267 k396 k579 k

Cash From Operating Activities

(7.4 m)(16.5 m)

Purchases of PP&E

(83 k)(118 k)

Cash From Investing Activities

4.7 m(14.5 m)

Cash From Financing Activities

688 k38.8 m

Aeglea Biotherapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2 Trials Products

1

Phase Approved

1

Phase I Trials Products

2
Report incorrect company information